Table 3.
Number (%) of patients reporting TEAES with incidence ≥5% in any group, on-therapy period, safety population
|
Placebo |
Desvenlafaxine |
Desvenlafaxine |
|
|---|---|---|---|
| (n=223) | 10 mg/d (n=226) | 50 mg/d (n=224) | |
|
Any TEAE |
147 (66) |
155 (69) |
154 (69) |
|
Gastrointestinal disorders |
|||
| Constipation |
5 (2) |
4 (2) |
15 (7) |
| Diarrhea |
11 (5) |
14 (6) |
17 (8) |
| Dry mouth |
11 (5) |
17 (8) |
20 (9) |
| Nausea |
14 (6) |
21 (9) |
32 (14) |
|
General disorders |
|||
| Fatigue |
4 (2) |
7 (3) |
13 (6) |
|
Infections |
|||
| Upper RTI |
11 (5) |
18 (8) |
12 (5) |
|
Metabolism and nutrition disorders |
|||
| Decreased appetite |
8 (4) |
9 (4) |
20 (9) |
|
Nervous system disorders |
|||
| Dizziness |
12 (5) |
9 (4) |
16 (7) |
| Headache |
17 (8) |
18 (8) |
16 (7) |
|
Psychiatric disorders |
|||
| Insomnia | 8 (4) | 11 (5) | 15 (7) |
RTI, respiratory tract infection; TEAE, treatment-emergent adverse event.